Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05123482 · ClinicalTrials.gov registry record · Phase 1

A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

A Phase 1 study of Breast Cancer and Ovarian Cancer, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 1
Development phase
460
Enrollment target
20
Study locations

NCT05123482 is a Phase 1 study of Breast Cancer and Ovarian Cancer that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 460 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (84% lower). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05123482, a Phase 1 study of Breast Cancer and Ovarian Cancer, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 1
Development phase
460 participants
Enrollment target
20
Study locations

Study Summary

This research study is studying a new compound, AZD8205, as a possible treatment for advanced or metastatic solid tumours alone or in combination with anti-cancer agents

Conditions Studied

Breast Cancer Ovarian Cancer Endometrial Cancer Squamous Non-Small Cell Lung Cancer Biliary Tract Carcinoma

Interventions

  • DRUG AZD8205
  • DRUG AZD8205 and AZD2936 (Rilvegostomig)
  • DRUG AZD8205 and AZD5305 (saruparib)
  • DRUG AZD8205 and AZD5305 (saruparib) and AZD2936 (rilvegostomig)
  • DRUG AZD8205 in combination with AZD9574

Study Locations (20)

Other

  • Research Site - Clayton
  • Research Site - Melbourne
  • Research Site - Nedlands
  • Research Site - Anderlecht
  • Research Site - Leuven

California

  • Research Site - Duarte
  • Research Site - Irvine
  • Research Site - Santa Monica
  • Research Site - Santa Rosa

New York

  • Research Site - Commack
  • Research Site - New York

Louisiana

  • Research Site - Shreveport

Maryland

  • Research Site - Baltimore

Massachusetts

  • Research Site - Boston

Missouri

  • Research Site - St Louis

New Mexico

  • Research Site - Albuquerque

Trial Details

FieldValue
Enrollment Target 460 participants
Start Date 2021-10-18
Est. Completion 2027-09-29
Phase Phase 1

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05123482

The ClinicalTrials.gov registry entry for NCT05123482 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 460 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (84% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which AZD8205 is the first listed.

NCT05123482 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, California, New York.

Frequently Asked Questions

What is clinical trial NCT05123482 about?

NCT05123482 is a clinical study titled "A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies". This research study is studying a new compound, AZD8205, as a possible treatment for advanced or metastatic solid tumours alone or in combination with anti-cancer agents

What is the current status of trial NCT05123482?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 460 participants. The study started on 2021-10-18. Estimated completion is 2027-09-29.

What conditions does trial NCT05123482 study?

This clinical trial studies the following conditions: Breast Cancer, Ovarian Cancer, Endometrial Cancer, Squamous Non-Small Cell Lung Cancer, Biliary Tract Carcinoma.

What interventions are being tested in trial NCT05123482?

The interventions under investigation include: AZD8205 (DRUG), AZD8205 and AZD2936 (Rilvegostomig) (DRUG), AZD8205 and AZD5305 (saruparib) (DRUG), AZD8205 and AZD5305 (saruparib) and AZD2936 (rilvegostomig) (DRUG), AZD8205 in combination with AZD9574 (DRUG).

Who is sponsoring clinical trial NCT05123482?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05123482 being conducted?

This trial has 20 study locations across California, Louisiana, Maryland, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

Ovarian Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.